Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa study of VR040 in idiopathic Parkinson's disease with motor off periods
2006-005509-79Phase 2Completed
- Sponsor
- Vectura
- Start
- Dec 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Parkinson's disease (PD) comparing VR040 ascending-dose with Placebo (2 arms). Primary endpoint: Maximum change in UPDRS III score from pre-dose to post-dose at the highest dose received. Started Dec 2006; status: completed.
02
Drugs
Aspirair
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2006-005509-79.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005509-79.